Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis

Taylor T. Teague1, Stephanie R. Payne2,3, Bryan T. Kelly1, Timothy M. Dempsey1, Rozalina G. McCoy2,4, Lindsey R. Sangaralingham2,3 and Andrew H. Limper1,2,5*

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of T2DM. There is growing evidence demonstrating metformin’s anti-fibrotic properties; however, there is little real-world clinical data regarding its potential effectiveness in IPF. This study aims to evaluate the clinical benefit of metformin in patients with IPF and T2DM.

Methods: This nationwide cohort study used de-identified administrative claims data from OptumLabs® Data Warehouse to identify 3599 adults with IPF and concomitant T2DM between January 1, 2014 and June 30, 2019. Two cohorts were created: a cohort treated with metformin (n = 1377) and a cohort not treated with metformin (n = 2222). A final 1:1 propensity score-matched cohort compared 1100 patients with IPF and T2DM receiving metformin to those with both diagnoses but not receiving metformin; matching accounted for age, sex, race/ethnicity, residence region, year, medications, oxygen use, smoking status, healthcare use, and comorbidities. Outcomes were all-cause mortality (primary) and hospitalizations (secondary).

Results: Among 2200 patients with IPF and T2DM included in this matched analysis, metformin therapy was associated with a reduction in all-cause mortality (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.36–0.58; p < 0.001) and hospitalizations (HR, 0.82; 95% CI, 0.72–0.93; p = 0.003) compared to patients not receiving metformin.

Conclusions: Among patients with IPF and T2DM, metformin therapy may be associated with improved clinical outcomes. However, further investigation with randomized clinical trials is necessary prior to metformin’s broad implementation in the clinical management of IPF.

Keywords: Idiopathic pulmonary fibrosis, Interstitial lung disease, Metformin, Type 2 diabetes mellitus, Mortality, Hospitalization

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease with high morbidity, mortality, and limited treatment options [1, 2]. Many therapies have been investigated as potential treatment options for IPF, but most have been ineffective [3–7] and, in some
cases, harmful [8–10]. Currently, only two medications are approved by the U.S. Food and Drug Administration (FDA) for IPF: the anti-fibrotic agents nintedanib and pirfenidone, which were approved in 2014 based on phase 3 clinical trials demonstrating slowed decline in lung function in patients with IPF [11, 12]. Subsequent pooled analyses [13–16] and observational studies [17, 18] suggested that their use reduces the risk of hospitalizations and improves mortality. Yet, only between 25 and 60% of patients with IPF are prescribed these anti-fibrotic medications [19–22]. Many factors contribute to their limited use including high costs (estimated at $100,000 per year) [23], side effects, uncertainty regarding IPF diagnosis, and treatment referral for presumed stable disease [19, 24]. Thus, additional therapies are needed to improve the health outcomes and reduce the risk of death among patients with IPF.

Type 2 diabetes mellitus (T2DM) is a common chronic health condition that is present in many patients with IPF [17]. Metformin is the first-line glucose-lowering medication in the management of T2DM [25]. In addition to metformin’s anti-glycemic control, there is accumulating evidence demonstrating anti-neoplastic [26–30], anti-aging [31–34], and anti-fibrotic properties [35–40]. Regarding its potential anti-fibrotic effect, initial in vivo studies showed that metformin reduced TGFβ1-induced fibrosis in human bronchial fibroblasts [41]. Several subsequent in vitro studies in murine models of bleomycin-induced lung fibrosis showed that mice treated with metformin after bleomycin exposure had decreased profibrotic markers [37, 38] as well as reduced histological [35–40] and radiological [40] signs of lung fibrosis compared to mice not receiving metformin. While these laboratory findings are intriguing, the concentrations and relative doses used in the cellular and rodent models were quite high, raising questions as to whether metformin would have similar impact on fibrosis in people with T2DM and IPF.

Beyond these pre-clinical findings, there is a paucity of clinical data regarding metformin’s effectiveness in patients with IPF. In fact, current evidence is limited to two studies. The first is a single post hoc analysis of three phase 3 clinical trials of pirfenidone where Spagnolo et al. investigated the effect of metformin on the clinical benefit of patients with IPF [42]. Metformin did not significantly impact clinical outcomes, including forced vital capacity (FVC) decline, 6-min walking distance (6MWD) decline, and death. However, this study was limited in its applicability and interpretation given the very small number of patients with metformin use (n=71; 11.4%) and lack of formal power analysis. The second study is a retrospective study where Lambert et al. evaluated for significance of cardiovascular drugs on disease progression and survival in patients with idiopathic pulmonary fibrosis [43]. Metformin was again found to have no significant impact on IPF progression (demonstrated by annual FVC and diffusing capacity of the lungs for carbon monoxide (DLCO) decline) or survival. However, this study was also limited by its very small number of patients receiving metformin (n=28).

Given the overall rarity of IPF, we chose to utilize a large healthcare claims database to enhance patient population diversity and size. To date, this study represents the only observational cohort analysis that evaluates for clinical benefit of metformin in patients with IPF in real-world practice. This nationwide cohort study sought to compare the risk of all-cause mortality among patients with IPF and concomitant T2DM receiving metformin to those not receiving metformin. In secondary analysis, the risk of hospitalizations was compared between IPF patients with and without metformin use.

Methods
Data source
We conducted a retrospective cohort study of de-identified administrative claims data from OptumLabs® Data Warehouse (OLDW), which is a large U.S. healthcare database containing information of enrollees in private and Medicare Advantage health plans [44]. Enrollees differ in age, race, ethnicity, incomes, and geographic location with representation from all 50 states. Per the Health Insurance Portability and Accountability Act of 1996 [45], institutional review board approval was not required since completely de-identified patient data was used.

Study population
The study population consisted of adults (≥18 years old) with IPF included in OLDW between January 1, 2014, and June 30, 2019. The diagnosis of IPF was established using either International Classification of Diseases, 9th edition (ICD-9) or International Classification of Diseases, 10th edition (ICD-10) codes for IPF or claims for ant-fibrotic medications present in medical and pharmacy claims, respectively. Patients were required to have either a single inpatient claim or two outpatient claims for IPF, as previously detailed by Dempsey et al. [17]. All patients were required to have 6 months of continuous enrollment in the health plan. The index date was defined as the first claims evidence of IPF after the 6-months enrollment criterion was met. Patients were also required to have a diagnosis of T2DM which was established using validated Healthcare Effectiveness Data and Information Set (HEDIS) criteria (an ICD-9 or ICD-10 billing code for T2DM, the use of insulin or oral anti-hyperglycemic agent, and either a single inpatient claim or two
outpatient claims for T2DM) [46]. We excluded patients with invalid demographic data and type 1 diabetes mellitus (T1DM), defined as an ICD-9 or ICD-10 billing code for T1DM.

**Comparator groups**
Patients with IPF were divided into those treated with metformin and those not treated with metformin, as seen in Fig. 1. The metformin-treated group included patients with a claim for metformin (any dose) any time prior to the index date and up until 40 days after the index date (to account for patients who started metformin after their index date). A 40-day window period was chosen because it was the median number of days (interquartile range 17, 78) to first metformin fill after index date. Most patients in the metformin-treated group had pharmacy claims for metformin that preceded their index date (1330/1377; 96.6%). Patients whose metformin prescription began >40 days after the index date were placed in the comparator group and censored at time of treatment.

---

**Fig. 1** Flow diagram of OptumsLab® cohort creation. **IPF** idiopathic pulmonary fibrosis, **T2DM** Type 2 diabetes mellitus, **T1DM** Type 1 diabetes mellitus.
initiation (161/2222; 7.2%). The comparator group included those who had no prior prescription for metformin (1849/2222; 83.2%), those who discontinued metformin prior to index date (118/2222; 5.3%), and those who had an invalid break in prescription (94/2222; 4.2%). Patients were then matched 1:1 on age, sex, race, residence region, year, medications (see “Independent variables” section), oxygen use, smoking status, healthcare use (see “Independent variables” section), and comorbidities (cardiac arrhythmia, congestive heart failure, chronic pulmonary disease, depression, hypertension, obesity, pulmonary circulation disorder, renal failure, rheumatoid arthritis, and valvular disease). As in our previous studies, we used oxygen use as a measure for disease severity matching since lung functions measures are not available in this dataset [17].

Independent variables
Comorbidities diagnosed in the 6 months prior to index date were identified using ICD-9 and ICD-10 diagnostic codes associated with medical claims. Comorbidity burden was evaluated using the Elixhauser sum of conditions [47]. Healthcare use including hospitalizations, primary care office visits, and pulmonologist office visits were captured by medical claims in the 6 months preceding the index date. Medication use (specifically oral corticosteroids, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), statins, sodium-glucose co-transporter-2 (SGLT2) inhibitors, insulin, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sulfonylureas, glitazones, and anti-fibrotics) was defined as having filled a prescription within 6 months prior to the index date. Oxygen use was identified using Healthcare Common Procedure Coding System indicating oxygen supplies during the 6 months prior to index date.

Follow up
Patients were followed until the end of the study period (June 30, 2019), end of enrollment in health insurance plan, death, start of first prescription fill for metformin (for untreated cohort) or metformin discontinuation (for treated cohort) which was defined as no prescription fill 30 days after the end supply.

Study outcomes
Primary outcome was all-cause mortality. Secondary outcome was all-cause hospitalizations.

Statistical analysis
We used propensity score matching to balance the differences in baseline characteristics between those receiving metformin and those not receiving metformin. A propensity score was estimated using logistic regression based on age, sex, race, residence region, year, medications (see “Independent variables” section), oxygen use, smoking status, healthcare use (see “Independent variables” section), and comorbidities (cardiac arrhythmia, congestive heart failure, chronic pulmonary disease, depression, hypertension, obesity, pulmonary circulation disorder, renal failure, rheumatoid arthritis, and valvular disease). Specifically, we used one-to-one nearest-neighbor caliper matching to match patients based on the logit of the propensity score [48]. We evaluated the standardized difference to assess the balance of covariates after matching, and a standardized difference ≤ 10% was considered acceptable [49]. When balance was not achieved through propensity score matching, we controlled for the unbalanced variable in the analysis. We then used Cox proportional hazard regression to compare mortality and hospitalizations in the matched cohort between patients on metformin and those not on metformin.

Falsification endpoint analysis was performed with one endpoint selected: fracture. Corresponding ICD-9 and ICD-10 diagnostic codes are listed in Table 1.

For a sensitivity analysis, we used inverse probability treatment weighting (IPTW) instead of propensity score matching to repeat the main analysis. A weight of 1/probability score was used for patients receiving metformin and 1/(1-probability score) for those not receiving metformin.

All analyses were conducted using SAS 9.4 (SAS Institute Inc.) and Stata version 15.1 (StataCorp).

| Diagnosis                        | ICD-9          | ICD-10         |
|---------------------------------|----------------|----------------|
| Idiopathic pulmonary fibrosis   | 516.31         | J84.112        |
| Diabetes mellitus, type 2       | 250. × 0, 250. × 2 | E11.xxx, D24.xxx |
| Diabetes mellitus, type 1       | 250. × 1, 250. × 3 | E10.xxx        |
| Fracture                        | 733.1x, 733.8x, 733.93, 733.94, 733.95, 733.96, 733.97, 733.98, 800–829 | M48.4x, M80.8x, M81.8, M83.3x-6x, S02.x, S12.x, S22.x, S32.x, S42.x, S52.x, S62.x, S72.x, S82.x, S92.x |

ICD-9: International Classification of Diseases, 9th edition; ICD-10: International Classification of Diseases, 10th edition
Results

Characteristics of the patient population
A total of 18,368 patients were examined for eligibility. There were 3599 (19.6%) patients with IPF and concomitant T2DM who met eligibility criteria and were included in the study. A total of 1377 (38.2%) were treated with metformin upon cohort entry. Of these 1377 patients, 1100 were 1:1 propensity score matched to patients with IPF and T2DM that had not received metformin, as seen in Fig. 1. The baseline clinical characteristics were well balanced between the groups with standardized differences < 10%, as shown under Table 2.

The mean ages of metformin-treated and untreated cohorts were 72.5 years (SD, 8.8) and 72.4 years (SD, 9.4), respectively. Men comprised 53.5% of the cohort untreated with metformin and 54.3% of the metformin-treated cohort. In the overall unmatched population, the percentage of patients with IPF that received an anti-fibrotic medication was 18.0% in the metformin-untreated cohort and 28.4% in the metformin-treated group. After 1:1 matching, the percentage of patients with IPF that received an anti-fibrotic medication was 23.6% in the metformin-untreated cohort and 23.2% in the metformin-treated group. The mean HbA1c was 6.9 (SD, 1.3) for the metformin-untreated cohort and 7.0 (SD, 1.2) for the metformin-treated cohort. The most prevalent comorbidities in the overall unmatched cohort were hypertension (82.2%), other chronic pulmonary conditions (67.2%), and congestive heart failure (37.7%). Mean durations of observation were 292.4 days (SD, 316.3) and 432.2 days (SD, 431.2) in the treated and untreated cohorts, respectively.

Association of metformin use with all-cause mortality
We next analyzed whether the use of metformin in patients with IPF and T2DM was associated with different all-cause mortality in the study population. Metformin use in the cohort diagnosed with both IPF and T2DM was associated with a significant decreased risk of all-cause mortality (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.36–0.58; \( p < 0.001 \)) compared to patients with both diagnoses that were not receiving metformin, as shown in Fig. 2A and Table 3.

Association of metformin use with hospitalizations
In a similar manner, we further sought to determine whether the use of metformin in patients with IPF and T2DM was associated with differing rates of hospitalization. Metformin use in this cohort was associated with a significant decreased risk of hospitalizations (HR, 0.82; 95% CI, 0.72–0.93; \( p = 0.003 \)), as demonstrated in Fig. 2B and Table 3.

Falsification analysis and sensitivity analysis
We then performed falsification endpoint analysis to test for confounding. These results are depicted in Table 4 and confirm our findings (HR, 0.75; 95% CI, 0.45–1.21; \( p = 0.23 \)). We also performed a sensitivity analysis using IPTW as seen in Table 5 which demonstrated similar results to our main analysis.

Effects of cardiovascular disease and renal disease on treatment effects of metformin in IPF with T2DM
Finally, we assessed the potential differences in metformin effect based upon whether patients had coded cardiovascular and renal diseases including arrhythmia, congestive heart failure (CHF), peripheral vascular disease (PVD) or renal disease. We did not observe any significant differences in the effects of metformin based on the presence or absence of these other coded diagnoses (Table 6).

Discussion
Metformin therapy in patients with IPF and concomitant T2DM was observed to have a significant 54% reduction in all-cause mortality in this large nationwide claims-based dataset. This is striking and represents a far stronger effect than previously observed with anti-fibrotic therapy in a similar population, where anti-fibrotic agents reduced the risk of all-cause mortality by 23% [17]. Metformin was further associated with an 18% lower risk of hospitalization for any cause. In a similar population, the two FDA-approved anti-fibrotic medications only had a trend towards decreased hospitalization [18].

The anti-fibrotic medications nintedanib and pirfenidone are currently the only FDA approved medications with demonstrated clinical benefit in IPF, yet they are underutilized with these medications being prescribed in only about 25% to 60% of patients with IPF in various studies [19–22]. Their use is limited due to high cost (estimated in the U.S. at $100,000 per year) [23], adverse side effects, uncertainties regarding the diagnosis of IPF, and treatment deferral for presumed stable disease [19, 24]. In contrast however, metformin is affordable, widely available, and safe. It serves as the first-line agent in the management of T2DM [25] and is used to treat select patients with pre-diabetes [50] as well as an alternative agent in patients with gestational diabetes [51] and polycystic ovarian syndrome [52, 53].

There are laboratory investigations that provide some insights into the possible effectiveness of metformin in IPF. As previously mentioned, metformin has been
### Table 2 Baseline characteristics of patients before and after propensity score matching

| No. (%) of patients | Before propensity score matching | Std diff | p value | After propensity score matching | Std diff | p value |
|---------------------|---------------------------------|----------|---------|---------------------------------|----------|---------|
|                     | No metformin (n = 2222) | Metformin (n = 1377) | | No metformin (n = 1100) | Metformin (n = 1100) | |
| Age, years          | <0.001 | 0.88   |         | 0.02 | 0.73   |         |
| Mean                | 73.4 (9.4) | 72.2 (8.5) | – | 72.4 (9.4) | 72.5 (8.8) | – |
| Median (IQR)        | 75 (68–82) | 73 (67–78) | – | 73 (67–80) | 74 (68–79) | – |
| Age group, years    | <0.001 | 0.63   |         | 0.004 | 0.99   |         |
| 18–54               | 89 (4.0) | 45 (3.3) | 0.0% | 48 (4.4) | 40 (3.6) | 0.0% |
| 55–64               | 278 (12.5) | 187 (13.6) | 3.2% | 155 (14.1) | 146 (13.3) | 0.0% |
| 65–74               | 729 (32.8) | 572 (41.5) | 18.1% | 419 (38.1) | 411 (37.4) | 0.6% |
| 75+                 | 1126 (50.7) | 573 (41.6) | 0.0% | 478 (43.5) | 503 (45.7) | 0.0% |
| Sex                 | 0.02 | 0.73   |         | 0.004 | 0.99   |         |
| Female              | 1042 (46.9) | 591 (42.9) | 0.0% | 511 (46.5) | 503 (45.7) | 2.0% |
| Male                | 1180 (53.1) | 786 (57.1) | 8.0% | 589 (53.5) | 597 (54.3) | 0.0% |
| Race                | 0.85 | 0.32   |         | 0.54  | 0.71   |         |
| White               | 1332 (59.9) | 794 (57.7) | 7.9% | 645 (58.6) | 647 (58.8) | 0.0% |
| Black               | 334 (15.0) | 170 (12.3) | 0.0% | 158 (14.4) | 151 (13.7) | 0.0% |
| Hispanic            | 358 (16.1) | 263 (19.1) | 7.9% | 191 (17.4) | 193 (17.5) | 0.0% |
| Asian               | 64 (2.9) | 60 (4.4) | 2.1% | 35 (3.2) | 34 (3.1) | 0.2% |
| Unknown             | 134 (6.0) | 90 (6.5) | 0.0% | 71 (6.5) | 75 (6.8) | 0.8% |
| Insurance           | 0.085 | 0.32   |         | 0.54  | 0.71   |         |
| Commercial          | 245 (11.0) | 149 (10.8) | – | 135 (12.3) | 120 (10.9) | – |
| Medicare advantage  | 1977 (89.0) | 1228 (89.2) | – | 965 (87.7) | 980 (89.1) | – |
| Census Region       | 0.60  | 1.00   |         | 0.004 | 0.99   |         |
| Midwest             | 535 (24.1) | 324 (23.5) | 0.0% | 243 (22.1) | 264 (24.0) | 0.0% |
| Northeast           | 336 (15.1) | 200 (14.5) | 0.0% | 166 (15.1) | 156 (14.2) | 3.0% |
| South               | 1167 (52.5) | 720 (52.3) | 0.0% | 600 (54.5) | 586 (53.3) | 0.9% |
| West                | 184 (8.3) | 133 (9.7) | 4.8% | 9 (8.3) | 94 (8.5) | 0.0% |
| Year                | 0.60  | 1.00   |         | 0.004 | 0.99   |         |
| 2014                | 392 (17.6) | 224 (16.3) | 0.0% | 187 (17.0) | 187 (17.0) | 2.0% |
| 2015                | 349 (15.7) | 204 (14.8) | 0.0% | 168 (15.3) | 171 (15.5) | 0.0% |
| 2016                | 416 (18.7) | 254 (18.4) | 0.0% | 217 (19.7) | 210 (19.1) | 1.7% |
| 2017                | 466 (21.0) | 288 (20.9) | 0.0% | 229 (20.8) | 229 (20.8) | 0.0% |
| 2018                | 409 (18.4) | 273 (19.8) | 3.6% | 202 (18.4) | 206 (18.7) | 0.0% |
| 2019*               | 190 (8.6) | 134 (9.7) | 4.1% | 97 (8.8) | 97 (8.8) | 0.0% |
| Anti-fibrotics      | 0.401 | 0.80   |         | 0.004 | 0.99   |         |
| Steroids            | 1009 (45.4) | 600 (43.6) | 0.0% | 505 (45.9) | 484 (44.0) | 2.0% |
| ACE inhibitor       | 530 (23.9) | 469 (34.1) | 22.6% | 344 (31.3) | 330 (30.0) | 1.7% |
| ARB                 | 558 (25.1) | 433 (31.4) | 14.1% | 331 (30.1) | 322 (29.3) | 0.1% |
| Statins             | 1296 (58.3) | 1005 (73.0) | 31.2% | 756 (68.7) | 739 (67.2) | 0.0% |
| SGLT2               | 28 (1.3) | 50 (3.6) | – | <0.001 | 13 (1.2) | 29 (2.6) | – |
| Insulin             | 664 (29.9) | 248 (18.0) | 0.0% | <0.001 | 231 (21.0) | 232 (21.1) | 0.0% |
| DPP4                | 229 (10.3) | 176 (12.8) | – | 0.02 | 143 (13.0) | 120 (10.9) | – |
| GLP-1               | 50 (2.3) | 63 (4.6) | – | 0.00 | 33 (3.0) | 42 (3.8) | – |
| Sulfonylureas       | 483 (21.7) | 426 (30.9) | 21.0% | <0.001 | 294 (26.7) | 294 (26.7) | 0.0% |
| Glitazones          | 58 (2.6) | 71 (5.2) | – | 0.00 | 38 (3.5) | 51 (4.6) | – |
| HbA1c labresult     | 0.00  | 0.04   |         | 0.004 | 0.99   |         |
shown to reduce lung fibrosis in murine models of bleomycin-induced lung fibrosis [35–40]. While the mechanism by which metformin reduces the development of lung fibrosis and accelerates its resolution is unknown, several hypotheses exist. The predominant hypothesis revolves around metformin-mediated stimulation of adenosine monophosphate-activated protein kinase (AMPK) [36, 38], which is a critical cellular energy sensor and regulator of cellular metabolism [54, 55]. AMPK protects cellular functions by converting cells to a catabolic state after metabolic stressors (i.e. hypoxia) interfere with adenosine triphosphate production [56, 57]. However other metformin-mediated signaling pathways have been implicated in the reduction of lung fibrosis including suppression of the pro-fibrotic cytokine insulin-like growth factor-1 (IGF-1) [40] and activation of BMP2-PPAR (bone morphogenetic protein-2-peroxisome proliferator-activated receptor) gamma that ultimately results in trans-differentiation of myofibroblasts to lipofibroblasts [39].

It is important to emphasize that our current study only observes an association of metformin use with better clinical outcomes in patients with both IPF and T2DM and does not establish causality nor provide any information as to whether this agent has altered the course of the fibrotic disease itself. Claims-based analyses such as this cannot assess the impact of metformin on surrogate endpoints of fibrotic disease progression, like FVC decline, DLCO decline, or 6-min walk test. Instead, the current study provides significant initial insights into the clinically meaningful and patient-centric endpoints of mortality and hospitalizations. Indeed, metformin may reduce mortality and hospitalizations through its effects on cardiovascular disease, respiratory complications of lung fibrosis, or overall health of the patient. Alternatively, perhaps there is an interaction between the anti-fibrotic

Table 2 (continued)

| Table 2 (continued) |
|---------------------|
| No. (%) of patients |
| Before propensity score matching | After propensity score matching |
| No metformin | Metformin (n = 1377) | Std diff | p value | No metformin | Metformin (n = 1100) | Std diff | p value |
| Mean (SD) | 6.9 (1.3) | 7.0 (1.2) | – | 6.9 (1.3) | 7.0 (1.2) | – |
| Median (IQR) | 6.6 (6.1–7.5) | 6.8 (6.2–7.5) | – | 6.6 (6.1–7.4) | 6.8 (6.2–7.5) | – |
| Primary care office visit | 1821 (82.0) | 1209 (87.8) | – | < 0.001 | 939 (85.4) | 964 (87.6) | – | 0.12 |
| Pulmonary office visit | 1237 (55.7) | 843 (61.2) | 11.3% | 0.00 | 652 (59.3) | 659 (59.9) | 0.7% | 0.76 |
| Baseline hospitalizations | | | | | | | |
| 0 | 1192 (53.6) | 925 (67.2) | 27.9% | 0.00 | 693 (63.0) | 701 (63.7) | 0.7% | 0.00 |
| 1 | 636 (28.6) | 326 (23.7) | 0.0% | 0.00 | 280 (25.5) | 277 (25.2) | 0.0% | 0.00 |
| 2+ | 394 (17.7) | 126 (9.2) | 0.0% | 0.00 | 127 (11.5) | 122 (11.1) | 0.0% | 0.00 |
| DME, oxygen | 1001 (45.0) | 587 (42.6) | 0.0% | 0.00 | 479 (43.5) | 473 (43.0) | 0.0% | 0.00 |
| Current smoker | 646 (29.1) | 395 (28.7) | 0.0% | 0.00 | 342 (31.1) | 321 (29.2) | 0.0% | 0.00 |
| Elixhauser comorbidity count | | | | | | | |
| Mean (SD) | 6.9 (3.1) | 5.8 (2.7) | – | < 0.001 | 6.1 (2.7) | 6.1 (2.8) | – | 0.00 |
| Median (IQR) | 7 (5–9) | 6 (4–7) | – | 0.00 | 6 (4–8) | 6 (4–8) | – | 0.00 |
| Elixhauser conditions | | | | | | | |
| Cardiac arrhythmia | 905 (40.7) | 405 (29.4) | 0.0% | < 0.001 | 357 (32.5) | 364 (33.1) | 1.3% | 0.75 |
| Congestive heart failure | 941 (42.3) | 417 (30.3) | 0.0% | < 0.001 | 371 (33.7) | 376 (34.2) | 4.3% | 0.82 |
| Chronic pulmonary disease | 1525 (68.6) | 895 (65.0) | 0.0% | < 0.001 | 737 (67.0) | 722 (65.6) | 0.0% | 0.00 |
| Depression | 368 (16.6) | 176 (12.8) | 0.0% | 0.00 | 160 (14.5) | 156 (14.2) | 0.0% | 0.00 |
| Hypertension | 1828 (82.3) | 1130 (82.1) | 0.0% | 0.00 | 916 (83.3) | 908 (82.5) | 0.0% | 0.00 |
| Obesity | 371 (16.7) | 227 (16.5) | 0.0% | 0.00 | 186 (16.9) | 183 (16.6) | 0.0% | 0.00 |
| Pulmonary circulation disorder | 512 (23.0) | 300 (21.8) | 0.0% | 0.00 | 250 (22.7) | 248 (22.5) | 0.0% | 0.00 |
| Renal failure | 764 (34.4) | 206 (15.0) | 0.0% | < 0.001 | 186 (16.9) | 203 (18.5) | 0.0% | 0.34 |
| Rheumatoid arthritis | 300 (13.5) | 167 (12.1) | 0.0% | 0.00 | 148 (13.5) | 143 (13.0) | 1.3% | 0.75 |
| Valvular disease | 575 (25.9) | 276 (20.0) | 0.0% | 0.00 | 239 (21.7) | 238 (21.6) | 0.0% | 0.96 |

SGLT2 sodium-glucose co-transporter-2, DPP4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, DME durable medical equipment

*From January 1,2019–June 30, 2019
A. Mortality

![Kaplan-Meier curve for mortality](image)

HR 0.46 (95% CI 0.36-0.58); \( P < 0.001 \)

B. Hospitalizations

![Kaplan-Meier curve for hospitalizations](image)

HR 0.82 (95% CI 0.72-0.93); \( P = 0.003 \)

**Fig. 2** Kaplan–Meier curves displaying cumulative risk of mortality (A) and hospitalizations (B) among patients with idiopathic pulmonary fibrosis with and without metformin use

**Table 3** Cox proportional hazard regression comparing mortality and hospitalizations among patients with idiopathic pulmonary fibrosis with and without metformin use

| Rate per 100 (95% CI) | Before propensity score matching | After propensity score matching | Hazard ratio (95% CI) | \( p \) value |
|------------------------|----------------------------------|---------------------------------|-----------------------|-------------|
|                        | No metformin \((n = 2222)\) | Metformin \((n = 1377)\) | No metformin \((n = 1100)\) | Metformin \((n = 1100)\) |
| Death                  | 25.1 (23.3, 27.1) | 10.5 (8.7, 12.5) | 20.6 (18.4, 23.2) | 10.5 (8.5, 12.8) | 0.46 (0.36, 0.58) | < 0.001 |
| Hospitalization        | 76.1 (72.0, 80.6) | 55.12 (50.4, 60.3) | 64.3 (59.2, 69.9) | 57.8 (52.4, 63.8) | 0.82 (0.72, 0.93) | 0.003 |
medications and metformin that potentiates each other’s effect—hence heightening the vast differences in observed outcomes. Metformin may offer cardiovascular protection to patients with IPF as it does in patients with T2DM [58–61]. In that light, it should be noted that cardiac disease is a common cause of death in patients with IPF, second only to respiratory failure [62, 63].

This study has several limitations. First, ICD billing codes were used to identify patients with IPF. IPF is difficult to diagnose and often requires multidisciplinary review for accurate diagnosis [64], so relying solely on billing codes for identification may result in inclusion of patients with erroneous diagnoses. However, we used the most accurate billing codes for IPF available for our review [65], a method that has been used previously in other studies [17, 22]. In addition, given the observational nature of this analysis, confounding factors cannot be completely eliminated, despite our rigorous statistical adjustments, falsification testing, and propensity score-matching. Our third limitation is due to cohort design as our treated cohort consisted of patients who filled a prescription for metformin. Unfortunately, in such a real-world analysis it is not possible to guarantee all patients reliably took the medication. Regardless, patients in our treated cohort consistently filled their prescriptions and those that did not refill metformin were excluded.

Conclusions
To our knowledge, this is the first real-world study assessing the clinical benefit of metformin in patients with IPF and T2DM. Several clinically relevant observations were gleaned from this U.S national, claims-based

| Table 4  | Falsification endpoint analysis |
|-----------------|---------------------------------|
| **Rate per 100 (95% CI)** |                                |
| **Before propensity score matching** | **After propensity score matching** | **Hazard ratio (95% CI)** | **p value** |
| --- | --- | --- | --- | --- |
| Fracture | 4.57 (3.81, 5.48) | 2.54 (1.75, 3.68) | 4.00 (3.05, 5.25) | 3.01 (2.05, 4.4) | 0.75 (0.45, 1.21) | 0.23 |

| Table 5  | Sensitivity analysis using inverse probably treatment weighting |
|-----------------|---------------------------------|
| **Before propensity score matching** | **After propensity score matching** | **Hazard ratio (95% CI)** | **p value** |
| --- | --- | --- | --- |
| **No metformin (n = 2222)** | **Metformin (n = 1100)** | **No metformin (n = 2222)** | **Metformin (n = 1100)** |
| Death | 25.1 (23.3, 27.1) | 10.5 (8.7, 12.5) | 22.5 (20.7, 24.6) | 11.6 (9.2, 14.7) | 0.46 (0.36, 0.58) | <0.001 |
| Hospitalization | 76.1 (72.0, 80.6) | 55.12 (50.4, 60.3) | 70.8 (65.7, 76.3) | 63.4 (55.7, 72.3) | 0.81 (0.72, 0.92) | 0.001 |

| Table 6  | Effects of cardiovascular and renal disease on treatment effects of metformin in IPF with T2DM |
|-----------------|---------------------------------|
| **Matched** | **Treated adjusted hazard ratio (95% CI)** | **p-value for interaction** |
| **No metformin (N = 1100)** | **Metformin (N = 1100)** | **No metformin (N = 1100)** | **Metformin (N = 1100)** |
| Arrhythmia | 30.64 (25.52, 36.78) | 17.07 (12.70, 22.94) | 0.49 (0.34, 0.69) |
| Yes | 16.80 (14.41, 19.57) | 7.67 (5.76, 10.21) | 0.42 (0.31, 0.60) |
| CHF | 30.96 (26.05, 36.79) | 21.52 (16.21, 28.55) | 0.58 (0.41, 0.81) |
| Yes | 16.04 (13.67, 18.83) | 6.64 (4.93, 8.96) | 0.39 (0.28, 0.55) |
| No | 24.12 (18.95, 30.71) | 15.00 (10.05, 22.37) | 0.56 (0.35, 0.90) |
| PVD | 19.76 (17.27, 22.59) | 9.43 (7.42, 11.98) | 0.44 (0.33, 0.58) |
| Renal | 25.12 (19.42, 32.50) | 15.19 (9.90, 23.29) | 0.55 (0.33, 0.90) |
| Yes | 19.72 (17.28, 22.49) | 7.32 (5.76, 12.08) | 0.44 (0.34, 0.58) |
| No | 0.52 | 0.39 | 0.39 | 0.39 |
retrospective cohort analysis, most importantly that metformin therapy in patients with IPF and T2DM was associated with a significant reduction in all-cause mortality. While these results are intriguing, caution is encouraged. Specific recommendations for the clinical management of idiopathic pulmonary fibrosis will require further investigation, including randomized clinical trials that ideally delineate between cardiovascular protection, disease stabilization, and improvement in the course of fibrosis by utilizing objective measures such as pulmonary function testing and thoracic imaging.

Abbreviations
IPF: Idiopathic pulmonary fibrosis; T2DM: Type 2 diabetes mellitus; TGFβ1: Transforming growth factor-beta 1; HR: Hazard ratio; CI: Confidence interval; U.S.: United States; FDA: Federal Drug Administration; FVC: Forced vital capacity; 6MWD: 6-Minute walking distance; DLCO: Diffusing capacity of the lungs for carbon monoxide; OPD: OptumLabs® Data Warehouse; ICD-9: International Classification of Diseases, Ninth Edition; ICD-10: International Classification of Diseases, Tenth Edition; HEDIS: Healthcare Effectiveness data and information set; T1DM: Type 1 diabetes mellitus; ACE: Angiotensin-converting enzyme; ARB: Angiotensin receptor blockers; SGLT2: Sodium-glucose co-transporter-2; DPP4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide-1; IPTW: Inverse probability treatment weighting; SD: Standard deviation; AMPK: Adenosine monophosphate-activated protein kinase; IGF-1: Insulin-like growth factor; BMP2-PPAR: Bone morphogenetic protein-2-peroxisome proliferator-activated receptor.

Acknowledgements
The authors thank the members of the Mayo Clinic Division of Pulmonary and Critical Care for helpful discussions during the course of these investigations.

Authors’ contributions
AHL made substantial contributions to the conception, designed the work, and revised the manuscript. SRP and LRS performed the analyses and were involved in the interpretation of data. TTT, BTX, TMD, RGM, and AHL drafted and revised the manuscript. All authors approved the submitted version and have agreed to be personally accountable for their contributions. All authors read and approved the final manuscript.

Funding
AHL receives supported by a grant from Three Lakes Foundation (Grant No. TL-1) and the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. The sponsors of this study had no role in the design of the study, or collection, analysis, and interpretation of data, or in writing of the manuscript.

Availability of data and materials
The data underly the results of this study are third party data owned by OptumLabs and contain sensitive patient information; therefore, the data is only available upon request. Interested researchers engaged in HIPAA compliant research may contact connected@optum.com for data access requests. The data use requires researchers to pay for rights to use and access the data.

Declarations
Ethics approval and consent to participate: These studies were conducted in compliance with all relevant regulations and guidelines. The Mayo Clinic Institutional Review Board has reviewed the use of data from the OptumLabs® Data Warehouse, a large US database with de-identified administrative claims data for individuals enrolled in private and Medicare Advantage health plans. In compliance with the Health Insurance Portability and Accountability Act and the U.S. National Institutes of Health, this research represents the use of completely de-identified healthcare claims data. Accordingly, this research is deemed exempt from being considered human subjects research by both the Mayo Clinic Institutional Review Board and the NIH.

Consent for publication
Since all subjects have been completely de-identified, and only grouped summary data is shown, the need for additional informed consent for publication has also been waived by the Mayo Clinic Institutional Review Board. Furthermore, since all patients have been completely deidentified, it is impossible to recontact any of these individuals.

Competing interests
There are no competing conflicts of interest for any of the authors with the content of this manuscript.

Author details
1 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 2 Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Harwick Building, Second Floor, 200 First Street SW, Rochester, MN 55905, USA. 3 OptumLabs, Eden Prairie, MN, USA. 4 Division of Community Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 5 Department of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Received: 5 November 2021 Accepted: 21 March 2022
Published online: 11 April 2022

References
1. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An Official ATS/ERS/ERS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(2):e3-19.
2. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/ERS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-68.
3. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–101.
4. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(12):1475–82.
5. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon-gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374(9685):222–8.
6. Daniel CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181(6):604–10.
7. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178(9):948–55.
8. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ, Pedrissone, azithromycin, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.
9. Raghu G, Behr J, Brown KK, Egan JJ, Kavuth SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641–9.
10. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88–95.
11. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
12. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.
13. Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson PO, et al. Predicting life expectancy for pefidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2017;23(3-Suppl):S17–S24.

14. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pefidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.

15. Richeldi L, Cotton V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSiSS(R) trials. Respir Med. 2016;113:74–9.

16. Lancaster C, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Lozaa L, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6(1):e000397.

17. Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168–74.

18. Kelly B, Thao V, Dempsey TM, Sangaralingham LR, Payne S, Limper AH. Anti-fibrotic therapy for idiopathic pulmonary fibrosis is associated with decreased mortality among hospitalized patients [abstract]. Am J Respir Crit Care Med. 2020;201:A7798.

19. Maher TM, Molina-Molina M, Russell A-M, Bonella F, Joueneau S, Ripamonti E, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis: insights from patient chart reading in five European countries. BMC Pulm Med. 2017;17(1):124.

20. Culver D, Ewe Y, Neely M, Belperio J, Bender S, De Andrade J, et al. Characteristics of patients with idiopathic pulmonary fibrosis (IPF) in the US: data from the IP-pro registry. Chest. 2018;154(4):397A-398A.

21. Flaherty K, De Andrade J, Lancaster L, Lim S, Lindell K, Nathan S, et al. Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry. Eur Respir J. 2018;52(suppl 62):PA2199.

22. Dempsey TM, Payne S, Sangaralingham LR, Yao X, Shah ND, Limper AH. Adoption of the anti-fibrotic medications pefidone and nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2021.

23. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–23.

24. Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019;20(1):205.

25. Pharmacologic Approaches to Glycemic Treatment. Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S11–24.

26. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Anti-cancer therapies affect risk of pancreatic cancer. J Clin Med. 2017;6(1):124.

27. Assurance NCfQ. National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS) 2020 Diabetes Mellitus Measures. 2020.

28. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1310–9.

29. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–61.

30. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3097.

31. American Diabetes Association. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S32–S36.

32. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, et al. Metformin attenuates lung fibrosis development via NOX4 suppression. Respir Res. 2016;17(1):107.

33. Gamad N, Malik S, Suchal K, Vasiht S, Tornar A, Arava S, et al. Metformin alleviates bleomycin-induced pulmonary fibrosis in rats: pharmacological effects and molecular mechanisms. Biomed Pharmacother. 2018;97:1544–53.

34. Rangarajan S, Bone NB, Zmijewska AA, Jiang S, Park DW, Bernard K, et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat Med. 2018;24(8):1121–7.

35. Sato N, Takasaka N, Yoshida M, Tsuibouchi K, Minagawa S, Araya J, et al. Metformin attenuates lung fibrosis development via NOX4 suppression. Respir Res. 2016;117:107.

36. Kim J, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis: time to treat. Respir Res. 2019;20(1):205.
59. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.
60. Roumie CL, Hung AM, Greely RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157(9):601–10.
61. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892–9.
62. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40.
63. King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis: implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014;189(7):825–31.
64. Moua T, Ryu JH. Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives. Ther Clin Risk Manag. 2019;15:73–81.
65. Vu A, Vasireddy A, Moua T, Baqir M, Ryu JH. Clarifying the diagnosis of post-inflammatory pulmonary fibrosis: a population-based study. Eur Respir J. 2019;54(1):1900103.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
**Terms and Conditions**

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”). Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial. These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)